Rani Therapeutics Holdings, Inc. filings document the regulatory record of a clinical-stage biotherapeutics company developing oral delivery technology for biologics and drugs. Form 8-K reports include quarterly and annual financial results, corporate updates, clinical and preclinical program disclosures, collaboration and license matters, and material agreements affecting the company’s operations and strategy.
The filing record also covers capital-structure activity involving Class A common stock, common warrants and pre-funded warrants, as well as Nasdaq continued-listing compliance notices. Proxy materials describe annual meeting matters, board elections, auditor ratification, governance procedures and stockholder voting mechanics for RANI’s public-company structure.
Rani Therapeutics Holdings, Inc. reported first quarter 2026 results, received a Nasdaq minimum bid-price deficiency notice, and announced a planned Chief Financial Officer transition. Contract revenue rose to $1.7 million from $0.2 million, while research and development and general and administrative expenses declined year over year.
The company recorded a net loss of $8.0 million versus $12.7 million a year earlier and ended March 31, 2026 with $43.4 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the fourth quarter of 2027. Nasdaq notified Rani that its shares failed to meet the $1.00 Minimum Bid Price Requirement for 30 consecutive business days, triggering a 180‑day cure period to November 9, 2026, with potential additional time if it moves to The Nasdaq Capital Market and, if needed, effects a reverse stock split. CFO Svai Sanford will resign following appointment of a successor and will receive nine months of base salary, COBRA premiums, and accelerated vesting of unvested equity under a separation agreement.
Rani Therapeutics Holdings, Inc. filing amends a previously reported Schedule 13G to show SymBiosis Capital Partners, LLC beneficially owns 4,433,620 shares of Class A Common Stock, representing 4.4% of the class. The filing lists sole voting and dispositive power over 4,433,620 shares. The amendment is signed by the reporting firm's Managing Partner on 05/15/2026.
Rani Therapeutics Holdings Inc reported that Vanguard Capital Management beneficially owns 5,109,368 shares of Common Stock, representing 5.12% of the class. The filing lists sole dispositive power over 5,109,368 shares and sole voting power over 486,801 shares. The disclosure is signed by Vanguard's Head of Global Fund Administration on 04/30/2026.
Rani Therapeutics Holdings, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 28, 2026. Investors will elect seven directors and ratify CBIZ CPAs P.C. as the independent registered public accounting firm for the year ending December 31, 2026.
The proxy statement details board independence, committee structures, risk oversight and prohibition on hedging, short sales and pledging. It also outlines executive pay, including salary cuts previously tied to financing, new option grants, a 2025 retention program, and severance and change in control protections for senior executives.
Rani Therapeutics Holdings, Inc. executive Alireza Javadi, Chief Technical Officer, reported his initial ownership of company securities. He directly holds 10,075 shares of Class A common stock, including 4,297 restricted stock units that vest in equal monthly installments from June 27, 2023 through March 27, 2027, subject to continued service.
He also holds several stock option awards over Class A common stock with exercise prices ranging from $0.6168 to $13.2100 per share and expirations between 2032 and 2035. One option grant is fully vested, while others vest monthly or in 25% annual installments over four-year periods beginning on December 27, 2023, March 21, 2024, and May 23, 2025, all contingent on his continued service.
Rani Therapeutics Holdings Inc ownership filing shows 0 shares beneficially owned by The Vanguard Group as reported in an amendment to a Schedule 13G/A. The filing explains an internal realignment effective January 12, 2026, causing certain Vanguard subsidiaries or business divisions to report separately and disaggregate prior beneficial ownership.
Rani Therapeutics Holdings is a clinical-stage biotherapeutics company developing the oral RaniPill capsule to replace injectable biologics, with both low-capacity GO and high-capacity HC versions. It focuses on obesity, immunology and partnered rare-disease programs and remains pre-revenue with ongoing operating losses.
As of June 30, 2025, non‑affiliate equity was valued at about $65.0 million based on a $0.51 share price. As of February 28, 2026, it had 99,721,927 Class A and 23,970,359 Class B shares outstanding. Certain Rani LLC holders may exchange units for 1,124,194 Class A shares.
In 2025, Rani strengthened liquidity through a $60.3 million private placement of Class A stock, pre-funded warrants and common warrants, a $3.0 million July offering, and warrant exercises totaling $8.4 million. It also eliminated debt by repaying the remaining $6.2 million loan principal plus associated interest and fees.
Pipeline highlights include initiating a Phase 1 trial of RT‑114, an oral GLP‑1/GLP‑2 dual agonist for obesity, advancing RT‑116 (oral semaglutide) toward Phase 1, and positive Phase 1 data for RT‑111 (oral ustekinumab). Rani entered a collaboration with Chugai for hemophilia product RT‑117, receiving a $10.0 million upfront payment and eligibility for substantial milestones and royalties, and a 50/50 collaboration with ProGen on RT‑114.
Rani Therapeutics reported fourth-quarter and full-year 2025 results while highlighting major strategic milestones. The company signed a collaboration and license agreement with Chugai worth up to $1.085 billion for oral delivery of a rare disease antibody using its RaniPill® platform and completed an oversubscribed private placement raising $60.3 million, including $6.0 million of debt conversion.
Cash, cash equivalents and marketable securities were $49.7 million as of December 31, 2025, up from $27.6 million a year earlier, and the company expects this, plus an anticipated Chugai milestone, to fund operations into the fourth quarter of 2027. Rani repaid all remaining Avenue debt in December 2025 and reported having no outstanding debt at year-end.
For 2025, contract revenue was $1.6 million, research and development expenses fell to $20.2 million and general and administrative expenses declined to $19.7 million, reflecting cost-containment efforts. Net loss narrowed to $41.0 million from $56.6 million in 2024, while the company advanced its pipeline with preclinical data for oral semaglutide and RT‑114 and initiation of a Phase 1 obesity study.
Investment Company, Inc., a Delaware investment adviser, reported beneficial ownership of 9,745,343 Class A shares of Rani Therapeutics Holdings, Inc., equal to 9.9% of the class as of 12/31/2025. The firm holds sole voting and dispositive power over these securities.
The position is held through three funds that own common shares, pre-funded warrants and warrants. These warrants may only be exercised so that total beneficial ownership does not exceed 9.99% of Rani’s outstanding shares. The filer certifies the stake is held in the ordinary course as a passive investment.